IGF1 and prostate cancer: The combined analysis showed that higher serum IGF-I levels were associated with an increased risk of prostate cancer (OR = 1.10, 95% CI: 1.02–1.18, P = 0.0136), with moderate heterogeneity (I2=50.6%).